Could 8 weeks of steroids be enough? new trial aims to cut treatment time for GCA
NCT ID NCT06833411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether people with giant cell arteritis (GCA) can safely take steroids for only 8 weeks instead of the usual 26 weeks when also using the drug tocilizumab. About 178 participants will be randomly assigned to one of two treatment lengths. The goal is to see if the shorter course prevents relapses just as well while reducing steroid-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Rheumatology and Immunology, Inselspital, University of Bern
Bern, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can frequent CRP checks prevent relapses in giant cell arteritis?
- Ultrasound clue vanishes days after steroids start in artery disease
- New Total-Body PET scanner could revolutionize vasculitis diagnosis
- New drug combo aims to tame blood vessel inflammation
- New ultrasound method could predict relapses in rare artery disease
- Which drug protects the heart better in giant cell arteritis?